In CRC-muc, we observed a lower frequency of p53 pathway alteration and a higher frequency of TGFβ signaling and RTK-RAS pathways alterations (19/48 (39.6%) vs. 153/189 (81%) FDR < 0.001, 28/48 (58.3%) vs. 35/189 (18.5%) FDR < 0.001, 43/48 (89.6%) vs. 140/189, FDR = 0.07). This evidence concerns the gene TP53 and colorectal carcinoma.